<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01209390</url>
  </required_header>
  <id_info>
    <org_study_id>OMCM-2010-01</org_study_id>
    <nct_id>NCT01209390</nct_id>
  </id_info>
  <brief_title>A Prospective, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects</brief_title>
  <acronym>OMCM</acronym>
  <official_title>A Prospective, Open Label, Multi-centre, Post-marketing Registry on the Use of ChondroMimetic for the Repair of Osteochondral Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TiGenix n.v.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TiGenix n.v.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this post-marketing study is to confirm the clinical efficacy and safety&#xD;
      outcome of treatment with ChondroMimetic in a patient population within the proposed&#xD;
      indication (osteochondral cartilage defects), over a 36 months post-implantation follow-up&#xD;
      period.&#xD;
&#xD;
      The primary objective is to collect post-marketing safety data in a real life setting by&#xD;
      means of (S)ADR reporting.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  Clinical outcome as assessed by patient reported EuroQoL-5D&#xD;
&#xD;
        -  Structural repair as assessed by MRI&#xD;
&#xD;
        -  The number of treatment failures and the time to treatment failure&#xD;
&#xD;
        -  The ease of use of ChondroMimetic as reported by the surgeon&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment rate&#xD;
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety data</measure>
    <time_frame>on ongoing basis up to 3 years</time_frame>
    <description>Safety data as measured by adverse device reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EuroQoL-5D</measure>
    <time_frame>baseline, 6, 12, 24, 36 months</time_frame>
    <description>The EQ-5D is a descriptive system of health-related quality of life states consisting of five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each of which can take one of three responses. The responses record three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI</measure>
    <time_frame>baseline, 12, 24, 36 months</time_frame>
    <description>Structural repair will be assessed by MRI. The available MRIs will be collected and scored by an independent radiologist, using the published MOCART score , and one additional item, level of the subchondral bone plate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure rate</measure>
    <time_frame>3 years</time_frame>
    <description>Treatment failure is defined as &quot;a re-intervention on the index lesion, prompted by persistence or recurrence of symptoms related to the index knee&quot;. The date of failure is the actual date of re-intervention.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Osteochondral Defects</condition>
  <arm_group>
    <arm_group_label>Osteochondral lesions</arm_group_label>
    <description>Patients with osteochondral lesions in the knee, the ankle, or other joint</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Chondromimetic</intervention_name>
    <description>The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.&#xD;
The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate.</description>
    <arm_group_label>Osteochondral lesions</arm_group_label>
    <other_name>Osteochondral repair plug</other_name>
    <other_name>CM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients will be recruited in selected centres, primary or secondary care, first line or&#xD;
        referral treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed patient informed consent&#xD;
&#xD;
          2. Shallow osteochondral defect ≤ 12 mm diameter and ≤ 8 mm depth in weight bearing area&#xD;
&#xD;
          3. Agree to actively participate in a rehabilitation protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe vascular or neurological disease&#xD;
&#xD;
          2. Uncontrolled diabetes&#xD;
&#xD;
          3. Severe degenerative joint disease&#xD;
&#xD;
          4. Pregnancy&#xD;
&#xD;
          5. Presence of infection at the site or in the joint space (e.g. osteomyelitis)&#xD;
&#xD;
          6. Diagnosis rheumatoidism&#xD;
&#xD;
          7. Advanced osteoarthritis as judged by the surgeon&#xD;
&#xD;
          8. Drug and/or alcohol abuse&#xD;
&#xD;
          9. Hypercalcemia&#xD;
&#xD;
         10. Known allergy to any of the components of the device (e.g. bovine collagen)&#xD;
&#xD;
         11. Bleeding disorders of any etiology&#xD;
&#xD;
         12. Steroidal or immunosuppressive maintenance therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uzsoki Hospital, Budapest, Hungary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3001</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>August 6, 2010</study_first_submitted>
  <study_first_submitted_qc>September 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2010</study_first_posted>
  <last_update_submitted>September 19, 2011</last_update_submitted>
  <last_update_submitted_qc>September 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteochondral</keyword>
  <keyword>regenerative</keyword>
  <keyword>repair</keyword>
  <keyword>cartilage lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteochondrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

